NCT00997373

Letrozole as a Treatment of Endometrial Cancer

Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: University of California, Davis · Academic / Other
• Sex: Female
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.

Conditions

• Endometrial Carcinoma

Interventions

Type	Name	Description
DRUG	Letrozole	2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks

Timeline

• Start date: 2009-10-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2009-10-19
• Last updated: 2017-05-30
• Results posted: 2015-04-06

Locations

2 sites across 1 country: United States